Triphase gets Health Canada nod to begin Phase I trial of marizomib to treat glioma
Drug development firm Triphase Accelerator has received approval from Health Canada to begin its Phase I trial of marizomib in combination with bevacizumab (Avastin) to treat patients with recurrent malignant glioma in Canada. (Source: Drug Development Technology)
Source: Drug Development Technology - September 27, 2015 Category: Pharmaceuticals Source Type: news

Amgen and Allergan's Phase III trial of ABP 215 meets primary and secondary endpoints
Amgen and Allergan have reported positive results from a Phase III trial that evaluated the efficacy and safety of ABP 215 compared with Avastin (bevacizumab) in adults with advanced non-squamous, non-small cell lung cancer (NSCLC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 23, 2015 Category: Pharmaceuticals Source Type: news

​Amgen, Allergan say their Avastin biosimilar showing positive results
Amgen Inc. and Allergan plc said their biosimilar candidate to treat lung cancer has shown positive results in a late-stage study that brings it one step towards coming to market as a competitor to Roche AG's Avastin. Thousand Oaks-based Amgen(Nasdaq: AMGN) and Irvine-based Allergan(NYSE: AGN) said their drug candidate, ABP 215, has shown to be as effective as Avastin in shrinking tumors and improving survival rates among patients with advanced non-small cell lung cancer. Avastin is Roche's best-selling… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 23, 2015 Category: Biotechnology Source Type: news

Are Medicare Prescription Benefits Too Stingy?
The bill she received in the mail revealed a staggering figure -- $9,225 for one infusion of Avastin, a chemotherapy drug. And she would need many more such infusions. Fortunately, the dollar amount is what medical experts call a “charge,” which in normal marketplaces refers to the amount a provider expects for the good or service in question, but in healthcare means: the amount the provider reports billing to the payer, which has almost nothing to do with what we expect the payer to pay. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 23, 2015 Category: Pharmaceuticals Authors: Peter Ubel Source Type: news

Chugai: Avastin Application for Approval of Additional Indication of Recurrent / Advanced Cervical Cancer in Japan
Dear Investor, please find attached a press release by Chugai (Source: Roche Investor Update)
Source: Roche Investor Update - September 17, 2015 Category: Pharmaceuticals Source Type: news

Adjuvant Bevacizumab Does Not Improve Survival in NSCLCAdjuvant Bevacizumab Does Not Improve Survival in NSCLC
The addition of bevacizumab to standard chemo regimens does not improve overall or disease-free survival in patients with resected non-small cell lung cancer (NSCLC). Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cancer patients are 'dying early because of the UK's stupid system'
Two Roche drugs, Avastin and Kadcyla, were de-listed by the Cancer Drugs Fund last week. Today, Severin Schwan, Roche CEO, said the NHS funding system is 'stupid' and threatens research. (Source: the Mail online | Health)
Source: the Mail online | Health - September 8, 2015 Category: Consumer Health News Source Type: news

Effectiveness and Costs of Bevacizumab vs Ranibizumab in DMEEffectiveness and Costs of Bevacizumab vs Ranibizumab in DME
A new head-to-head trial compares the efficacy and economic value of these two anti-VEGF agents for DME. Which one has the edge? BMC Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2015 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

High profile treatments cut from cancer drugs fund
High profile cancer treatments including Roche’s Kadcyla and Avastin are to be removed from the cancer drugs fund. (Source: HSJ)
Source: HSJ - September 4, 2015 Category: UK Health Source Type: news

Industry Complains to EU Over French Law Pushing Cheap Eye DrugIndustry Complains to EU Over French Law Pushing Cheap Eye Drug
Europe's pharmaceuticals industry said on Tuesday it had filed a complaint with the European Commission against a French law promoting the use of Roche's cancer drug Avastin as a cheap treatment for wet age-related macular degeneration (AMD). Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 2, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Industry complains to EU over French law pushing cheap eye drug
(Reuters) - Europe's pharmaceuticals industry said on Tuesday it had filed a complaint with the European Commission against a French law promoting the use of Roche's cancer drug Avastin as a cheap eye treatment. (Source: Reuters: Health)
Source: Reuters: Health - September 1, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Endophthalmitis Risk No Greater With Avastin Than Lucentis Endophthalmitis Risk No Greater With Avastin Than Lucentis
FDA-proposed restrictions on the ophthalmic use of bevacizumab through compounding pharmacies may be unnecessary, researchers find. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 17, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Eye Infection Risk Similar for Avastin, Lucentis Injections (CME/CE)
(MedPage Today) -- Calls FDA guidance limiting ophthalmic bevacizumab compounding into question (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 14, 2015 Category: Geriatrics Source Type: news

Drug Avastin Not Linked to Higher Risk of Blindness: Study
Title: Drug Avastin Not Linked to Higher Risk of Blindness: StudyCategory: Health NewsCreated: 8/13/2015 12:00:00 AMLast Editorial Review: 8/14/2015 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - August 14, 2015 Category: Opthalmology Source Type: news

Drug Avastin Not Linked to Higher Risk of Blindness
Researchers found medication didn't increase odds of serious eye infection Source: HealthDay Related MedlinePlus Pages: Drug Safety, Eye Infections, Retinal Disorders (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 13, 2015 Category: Consumer Health News Source Type: news

AstraZeneca chases biosimilar Avastin drug with Japanese group
LONDON (Reuters) - AstraZeneca is dipping its toe in the biosimilars market, as a way to make future cancer drug cocktails more affordable, by linking with a Japanese group to develop a copy of Roche's blockbuster medicine Avastin. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Bevacizumab vs Ranibizumab for Macular Edema Due to BRVOBevacizumab vs Ranibizumab for Macular Edema Due to BRVO
How does treatment between these two anti-VEGF agents compare in terms of visual acuity and central retinal thickness outcomes? The British Journal of Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - July 23, 2015 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news

Bevacizumab for Glioblastoma: Mayo Clinic Radio Health Minute
In this Mayo Clinic Radio Health Minute, Dr. Derek Johnson comments on a study which looked at whether certain medication improves survival for patients with glioblastoma, an aggressive form of brain cancer. To listen, click the link below. Bevacizumab for Glioblastoma (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 22, 2015 Category: Databases & Libraries Source Type: news

Drug Dosages Questioned in Diabetic Macular Edema TrialDrug Dosages Questioned in Diabetic Macular Edema Trial
Experts wonder whether increased doses might eliminate the advantages seen with aflibercept over bevacizumab and ranibizumab in a diabetic macular edema trial. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Patients with lowest BMI have shortest survival in pooled analysis of bev in mCRC
(European Society for Medical Oncology) Patients with the lowest body mass index had the shortest overall survival in an analysis of bevacizumab studies in metastatic colorectal cancer presented for the first time at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 1, 2015 Category: Global & Universal Source Type: news

Adding Bevacizumab for Advanced Endometrial CancerAdding Bevacizumab for Advanced Endometrial Cancer
Dr Maurie Markman discusses the most clinically relevant research abstract on the gynecologic cancers as presented at ASCO 2015. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 29, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Bevacizumab 'Not Cost-effective for Glioblastoma'Bevacizumab 'Not Cost-effective for Glioblastoma'
The drug is not cost-effective as a first-line treatment for glioblastoma and does not merit further investigation, say Canadian researchers. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Bevacizumab May Be Next Standard of Care for Mesothelioma
Discussions About Mesothelioma at ASCO Meeting There were other abstracts involving mesothelioma presented at the ASCO, adding even more optimism about potential treatment advances. Dr. Raffit Hassan, mesothelioma specialist from the National Cancer Institute, detailed results of a phase I trial involving immunotherapy drug CRS-207 in combination with standard chemotherapy. Disease control was obtained in 30 of the 32 trial participants. There was partial response in 19 patients and stable disease in 11. CRS-207 is given by vaccination. Median duration of response was 5 months and median progression-free survi...
Source: Asbestos and Mesothelioma News - June 5, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Avastin Combo Boosts Disease-Free Survival in Breast Cancer
(MedPage Today) -- But Avastin again fails to prolong life (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 2, 2015 Category: Hematology Source Type: news

Paradigm-Changing Triplet Therapy for MesotheliomaParadigm-Changing Triplet Therapy for Mesothelioma
Bevacizumab added to standard of care provided significantly longer overall survival for patients with malignant pleural mesothelioma. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 1, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

ASCO: Bevacizumab Falls Short Again
(MedPage Today) -- Trial is "technically positive" but won't restore sheen to failed breast cancer drug. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 1, 2015 Category: Hematology Source Type: news

Randomized Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Overall Survival and Emergence of Long-term Survival Benefit; Primary Endpoint of PFS6 Met
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - May 31, 2015 Category: Pharmaceuticals Source Type: news

Collaborative group phase III study shows Roche’s Avastin improves survival in patients with mesothelioma - a devastating type of thoracic cancer
Roche announced today phase III results from a collaborative group study that showed that patients with malignant pleural mesothelioma, a rare type of cancer that affects the lining of the lungs, lived significantly longer when treated with Avastin in combination with standard therapy (pemetrexed and cisplatin chemotherapy) compared to standard therapy alone. (Source: Roche Investor Update)
Source: Roche Investor Update - May 30, 2015 Category: Pharmaceuticals Source Type: news

Pharmacists Warn of Ophthalmic Drug ShortagesPharmacists Warn of Ophthalmic Drug Shortages
Compounding pharmacists say new regulations could limit the supply of ophthalmic drugs, such as macular degeneration formulations of bevacizumab. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 29, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Avastin, the first cervical cancer drug for 10 years
Patients will have access via the Cancer Drugs Fund (CDF) until it is considered for routine NHS use. It has been available in England via the CDF since last March pending licensing. (Source: the Mail online | Health)
Source: the Mail online | Health - April 28, 2015 Category: Consumer Health News Source Type: news

EU approves Roche's Avastin plus chemotherapy for women with advanced cervical cancer
Roche announced today that the European Commission (EU) approved Avastin (bevacizumab) in combination with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy) for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. (Source: Roche Media News)
Source: Roche Media News - April 8, 2015 Category: Pharmaceuticals Source Type: news

EU approves Roche's Avastin plus chemotherapy for women with advanced cervical cancer
Roche announced today that the European Commission (EU) approved Avastin (bevacizumab) in combination with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy) for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. (Source: Roche Investor Update)
Source: Roche Investor Update - April 8, 2015 Category: Pharmaceuticals Source Type: news

Roche's Avastin plus chemotherapy receives European approval for cervical cancer
Switzerland-based Roche has received approval from the European Commission for its Avastin (bevacizumab) in combination with standard chemotherapy to treat adult patients with persistent, recurrent or metastatic carcinoma of the cervix. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 7, 2015 Category: Pharmaceuticals Source Type: news

GMC steps into eye drug row
Regulator says controversy surrounding use of Avastin places doctors in "invidious" position Related items from OnMedicaGPs slam Superdrug home genetics test kitNovartis accused of attempt to derail eye drug trialsParacetamol "does not help back pain or arthritis"Prescribing rights of allied health professionals to be widenedGPs under spotlight in drive to cut antibiotic prescribing (Source: OnMedica Latest News)
Source: OnMedica Latest News - April 7, 2015 Category: UK Health Source Type: news

New Mesothelioma Treatment Options Are Emerging for Patients
Although no definitive cure is in sight, the treatment of malignant pleural mesothelioma has entered a promising, much-anticipated phase that goes beyond the multimodal approach that has been the standard of care at specialty centers for the past several years. There is new hope on the horizon. Thoracic surgeon and renowned mesothelioma specialist Dr. Robert Cameron, along with scientist Raymond Wong, Ph.D., and thoracic and cardia surgeon Dr. Svetlana Kotova, recently detailed the changing face of therapy in a paper they co-authored and published in the Cancer Management Research Journal . "With all the ongoing r...
Source: Asbestos and Mesothelioma News - April 2, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Bevacizumab in Ovarian Cancer Extends Overall SurvivalBevacizumab in Ovarian Cancer Extends Overall Survival
Adding the antiangionic agent to combination chemotherapy shows a clinically meaningful improvement in overall survival compared with standard chemotherapy alone. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 1, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Mixed Results for Avastin Plus Chemo in Ovarian Cancer (CME/CE)
(MedPage Today) -- Regimen improves survival but study misses cutoff for statistical significance. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 30, 2015 Category: Hematology Source Type: news

Women with ovarian cancer gain extra months with addition of drug to standard chemotherapy
Overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 28, 2015 Category: Science Source Type: news

Is Bevacizumab Truly a New Standard in Cervical Cancer?Is Bevacizumab Truly a New Standard in Cervical Cancer?
New data on quality of life show 'convincingly' that it is not adversely affected, but does it all add up to a new standard? Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 25, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

VBL Therapeutics Reports Interim Topline Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM)
Interim Data Demonstrate Statistically Significant Improvement in Overall Survival in Patients Treated With VB-111 in Combination With Bevacizumab (Avastin(R)) TEL AVIV, Israel, March 25, 2015 -- (Healthcare Sales & Marketing Network) -- VBL Therapeutic... Biopharmaceuticals, OncologyVBL Therapeutics, VB-111, glioblastoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 25, 2015 Category: Pharmaceuticals Source Type: news

Avastin Macular Edema and Degeneration Market Analysis & Forecast...
RnRMarketResearch.com adds “Avastin (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023” to its store.(PRWeb March 17, 2015)Read the full story at http://www.prweb.com/releases/avastin-macular-edema/degeneration-market-2023/prweb12588888.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 19, 2015 Category: Pharmaceuticals Source Type: news

A new study for people with Renal Cell Carcinoma (RCC)
This study will explore the effectiveness of the experimental drug known as CRLX101 combined with bevacizumab (Avastin), in patients with metastatic renal cell carcinoma (RCC).03/04/2015 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 4, 2015 Category: Cancer & Oncology Source Type: news

Genentech delves into apps to link with breast cancer patients
Over years of cancer drug research, Genentech Inc. has kept a keen watch on patients: how they respond to drugs in a clinical trial, for example, or what patients need in a next-generation drug. Yet even as the South San Francisco-based biotech unit of Swiss drug giant Roche developed some of the best-selling and effective cancer drugs — Avastin and Herceptin among them — it heard from patients that the medications themselves were not enough. Breast cancer patients, in particular, wanted to… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 3, 2015 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

EU recommends Roche’s Avastin plus chemotherapy to treat cervical cancer
The European Union's (EU) Committee for Medicinal Products for Human Use (CHMP) has recommended the use of Avastin (bevacizumab) in combination with standard chemotherapy (paclitaxel and cisplatin or paclitaxel and topotecan in patients who cannot re… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 2, 2015 Category: Pharmaceuticals Source Type: news

ABPI respond to call to allow off-label prescribing of Avastin
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2015 Category: Drugs & Pharmacology Source Type: news

Roche says EU agency recommends Avastin for cervical cancer
ZURICH (Reuters) - Roche said on Friday that European regulators had recommended approval of its drug Avastin in combination with chemotherapy as a treatment for women with an advanced form of cancer of the cervix. (Source: Reuters: Health)
Source: Reuters: Health - February 27, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Roche’s Avastin plus chemotherapy receives positive recommendation from CHMP for EU approval in advanced cervical cancer
Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of Avastin® (bevacizumab) in combination with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy) for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. (Source: Roche Media News)
Source: Roche Media News - February 27, 2015 Category: Pharmaceuticals Source Type: news

Roche’s Avastin plus chemotherapy receives positive recommendation from CHMP for EU approval in advanced cervical cancer
Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the use of Avastin® (bevacizumab) in combination with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy) for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. (Source: Roche Investor Update)
Source: Roche Investor Update - February 27, 2015 Category: Pharmaceuticals Source Type: news

UK doctors urge use of Roche's Avastin as cheap eye drug
LONDON (Reuters) - British doctors called on Tuesday for Roche's cancer drug Avastin to be made routinely available as a cheap alternative for treating people with a debilitating eye disorder. (Source: Reuters: Health)
Source: Reuters: Health - February 24, 2015 Category: Consumer Health News Tags: healthNews Source Type: news